Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AG + FOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
AG + FOLFIRINOX is a sequential chemotherapy regimen being investigated as a neoadjuvant and adjuvant treatment for patients with resectable pancreatic cancer. The regimen consists of two distinct phases: the AG regimen, which combines nab-paclitaxel (albumin-bound paclitaxel) and gemcitabine, followed by the FOLFIRINOX regimen, which includes oxaliplatin, irinotecan, leucovorin (folinic acid), and 5-fluorouracil (5-FU). This sequential approach is designed to utilize multiple cytotoxic mechanisms—including microtubule stabilization, DNA synthesis inhibition, DNA cross-linking, and topoisomerase I inhibition—to maximize therapeutic efficacy and improve surgical outcomes in pancreatic adenocarcinoma. The regimen is currently being evaluated in a Phase II clinical trial sponsored by the Tianjin Medical University Cancer Institute and Hospital.
- Brand names
- AbraxaneCamptosarEloxatin
- Other names
- AG followed by FOLFIRINOXSequential AG and FOLFIRINOXAG + FOLFIRINOX-Tianjin Medical University Cancer Institute and Hospital-pancreatic cancer
02
Targets
TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on AG + FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AG + FOLFIRINOX.